Ras: Small Molecules and Peptides
The Ras proteins (H-Ras, N-Ras, and two splice variants of K-Ras) define a closely related family of 21 kDa GTPases that cycle between GTP-bound active and GDP-bound inactive states at the cytoplasmic face of the plasma membrane. Receptor tyrosine kinases and G-protein coupled receptors activate Ras, and effectors include Raf and PI 3-kinase. Activating mutations of Ras, which impair GTPase activity and stabilize the active state, are found in nearly one-third of all human cancers.
11 results for "Ras Small Molecules and Peptides" in Products
11 results for "Ras Small Molecules and Peptides" in Products
Ras: Small Molecules and Peptides
The Ras proteins (H-Ras, N-Ras, and two splice variants of K-Ras) define a closely related family of 21 kDa GTPases that cycle between GTP-bound active and GDP-bound inactive states at the cytoplasmic face of the plasma membrane. Receptor tyrosine kinases and G-protein coupled receptors activate Ras, and effectors include Raf and PI 3-kinase. Activating mutations of Ras, which impair GTPase activity and stabilize the active state, are found in nearly one-third of all human cancers.
Potent farnesyl diphosphate (FPP) synthase inhibitor
| Alternate Names: | Zometa |
| Chemical Name: | [1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic acid |
| InChi Key: | XRASPMIURGNCCH-UHFFFAOYSA-N |
| Purity: | ≥98% (HPLC) |
Ras signaling inhibitor; inhibits Ack1 and GCK
| Chemical Name: | N-[3-[1,4-Dihydro-1-methyl-7-[(6-methyl-3-pyridinyl)amino]-2-oxopyrimido[4,5-d]pyrimidin-3(2H)-yl]-4-methylphenyl]-3-(trifluoromethyl)benzamide |
| Purity: | ≥98% (HPLC) |
Leucyl-tRNA synthase (TRS)/Ras-related GTP-binding protein D (RagD) interaction inhibitor
| Chemical Name: | 4-[2,5-Dihydro-2,3-dimethyl-4-(1-methylethyl)-5-oxo-1H-pyrazol-1-yl]-N-(2-phenoxyethyl)benzenesulfonamide |
| Purity: | ≥98% (HPLC) |
Inhibits KRas localization to the plasma membrane; also L-type calcium channel blocker
| Chemical Name: | N-(3,3-Diphenylpropyl)-α-methylbenzylamine hydrochloride |
| Purity: | ≥98% (HPLC) |
Potent and selective KRASG12C inhibitor
| Alternate Names: | Sotorasib |
| Chemical Name: | (1R)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-[4-methyl-2-(1-methylethyl)-3-pyridinyl]-4-[(2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl]pyrido[2,3-d]pyrimidin-2(1H)-one |
| Purity: | ≥98% (HPLC) |
Selective KRAS Degrader (PROTAC®)
| Chemical Name: | (2S,4R)-1-((S)-2-(3-(3-((S)-2-(((7-(8-Chloronaphthalen-1-yl)-4-((S)-3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)pyrrolidin-1-yl)propoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide |
| Purity: | ≥95% (HPLC) |
Selectively kills mutant HRAS-expressing cells; glutathione peroxidase inhibitor; induces ferroptosis
| Chemical Name: | [4-[Bis(4-chlorophenyl)methyl]-1-piperazinyl](5-methyl-4-nitro-3-isoxazolyl)methanone |
| Purity: | ≥98% (HPLC) |
High affinity PDEδ-KRas interaction inhibitor; binds to PDEδ
| Chemical Name: | 2-[4-[(2S)-2-(2-Phenyl-1H-benzimidazol-1-yl)-2-(4-piperidinyl)ethoxy]phenyl]-1-(phenylmethyl)-1H-benzimidazole trihydrochloride |
| Purity: | ≥98% (HPLC) |
Mutation-selective inhibitor of KRASG12C
| Alternate Names: | Adagrasib |
| Chemical Name: | 4-[7-(8-Chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-[[(2S)-1-methyl-2-pyrrolidinyl]methoxy]pyrido[3,4-d]pyrimidin-4-yl]-1-(2-fluoro-1-oxo-2-propen-1-yl)-(2S)-2-piperazineacetonitrile |
| Purity: | ≥98% (HPLC) |
Negative control for LC 2 (Cat. No. 7420)
| Chemical Name: | (2S,4S)-1-((S)-2-(3-(3-((S)-2-(((7-(8-Chloronaphthalen-1-yl)-4-((S)-3-(cyanomethyl)-4-(2-fluoroacryloyl)piperazin-1-yl)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-2-yl)oxy)methyl)pyrrolidin-1-yl)propoxy)propanamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide |
| Purity: | ≥95% (HPLC) |
PDEδ autophagy-tethering compound (ATTEC) Degrader
| Chemical Name: | N-(6-(2-(2,6-Dibromo-4-((5-iodo-2-oxoindolin-3-ylidene)methyl)phenoxy)acetamido)hexyl)-4-(3,4-dimethyl-7-oxo-2-(p-tolyl)-2,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)butanamide |
| Purity: | ≥98% (HPLC) |
